Stifel raises Rapport Therapeutics stock price target to $56 on positive trial data

Rapport Therapeutics (RAPP) shares surged over 13% following strong Phase 2a trial results for its epilepsy drug candidate, RAP-219, which demonstrated a 77.8% median reduction in focal onset seizures and a benign safety profile. Stifel subsequently raised its price target to $56 from $35, maintaining a Buy rating, citing the drug's significant effect size despite a small sample, which substantially boosts confidence for successful Phase 3 trials and positions RAP-219 as a potential differentiated treatment for drug-resistant epilepsy. Other analysts, including TD Cowen and JMP Securities, also reiterated positive outlooks, underscoring the drug's potential to significantly impact the treatment landscape for drug-resistant epilepsy.

Analysis

Rapport Therapeutics (RAPP) has received a significant vote of confidence from the market and sell-side analysts following positive top-line results from its Phase 2a trial for RAP-219 in drug-resistant focal onset seizures. The trial achieved its primary endpoint with a 77.8% median reduction in clinical seizures, and notably, 24% of participants experienced complete seizure freedom. This strong efficacy data prompted Stifel to raise its price target to $56 from $35 while maintaining a Buy rating. Stifel's conviction is rooted in an effect size described as "so large" that it materially increases the probability of success for upcoming Phase 3 trials, even if the effect moderates in a larger, placebo-controlled study. Reinforcing the positive outlook, the drug's safety and tolerability profile was deemed "fairly benign." This sentiment was echoed by TD Cowen and JMP Securities, which both reiterated positive ratings, solidifying the view that RAP-219 is a promising candidate with potential to offer a differentiated profile in the epilepsy market. The stock's subsequent 13% intraday gain to $31.33 reflects this optimism, although investors should note the result was from a small, open-label study without a placebo control, which remains a key consideration for future development.

Key Decisions for Investors

• Given the highly positive Phase 2a data and significant analyst price target upgrades, investors with a high-risk tolerance for clinical-stage biotechs could view the current share price as an attractive entry point ahead of the pivotal Phase 3 program.
• The primary risk to monitor is the transition to larger, placebo-controlled Phase 3 trials; investors should scrutinize the trial design and be aware that the exceptional effect size seen in this small study may not be fully replicated.
• With Stifel's new $56 price target substantially above the prior consensus range high of $42, investors should assess whether the potential reward justifies the inherent clinical and regulatory risks associated with drug development.